Objective: Post-operative concurrent chemoradiotherapy significantly improves the rates of locoregional control and disease-free survival in high-risk patients but has significant adverse effects. Percutaneous endoscopic gastrostomy and opioid-based pain control increase treatment completion rates but can result in dysphagia. Methods: The rate and duration of use of prophylactically placed percutaneous endoscopic gastrostomies were evaluated in 43 patients who underwent post-operative radiotherapy or chemoradiotherapy from April 2007 through March 2010. All patients completed treatment and received 60 Gy or more of radiotherapy. Results: Thirty four of 43 patients (79.1%) used percutaneous endoscopic gastrostomies, which could later be removed in 25 of 34 patients. The median period of use was 108 days. Only one disease-free patient was permanently dependent on percutaneous endoscopic gastrostomy feeding. The frequency of percutaneous endoscopic gastrostomy use among patients with oral, oropharyngeal and hypopharyngeal cancer was 91.7, 100 and 54.5%, respectively. Conclusions: Prolonged percutaneous endoscopic gastrostomy use is not required in patients receiving post-operative chemoradiotherapy and will not lead to dysphagia.
INTRODUCTION
Patients undergoing resection of head and neck cancers with positive surgical margins or extranodal spread of disease are considered to be at high risk for recurrence. Concurrent postoperative chemoradiotherapy for such patients significantly improves the rates of local and regional control and prolongs disease-free survival. However, chemoradiotherapy is associated with a substantial increase in adverse effects (1, 2) .
Patients with head and neck cancer receiving radiotherapy or chemoradiotherapy are at a considerable risk of malnutrition, with 75 -80% of patients experiencing a weight loss during treatment (3 -6) of up to 15 or 20% (7, 8) . Radiotherapy-related toxicities include painful mucositis, dysgeusia, xerostomia, odynophagia, thickened secretions and anorexia (7,9 -14) . Treatment can, therefore, decrease oral intake by physical means and by decreasing a patient's motivation to eat.
Enteral feeding refers to the delivery of nutrients directly into the stomach via a feeding tube device, such as a nasogastric feeding tube or a gastrostomy tube (15) . Enteral tube feeding is used for patients who cannot obtain adequate oral intake of nutrients from food or oral nutritional supplements or both or who cannot eat or drink safely (16) . Enteral feeding can also be used during and after treatment to provide nutritional support to patients with head and neck cancers who are unable to meet their nutritional requirements because of treatment-related side effects.
In our hospital, patients receiving post-operative chemoradiotherapy undergo prophylactic percutaneous endoscopic gastrostomy (PEG). With PEG tube feeding and opioid-based pain control, the completion rate of chemoradiotherapy is increased (17) .
Prophylactic PEG has been shown to significantly reduce both mean weight loss and rate of hospitalization during radiotherapy (18 -21) and to result in fewer unscheduled treatment interruptions (22) . Therefore, in the present study, we examined the rate and duration of use of prophylactically placed PEGs for enteral feeding during post-operative radiotherapy or chemoradiotherapy among patients with head and neck cancers.
PATIENTS AND METHODS
A chart review was performed. We evaluated the rate and duration of use of prophylactically placed PEG tubes for enteral feeding in 43 patients who underwent post-operative radiotherapy or chemoradiotherapy from April 2007 through March 2010 at the National Cancer Research Center East Hospital. Age, sex, location and stage of cancer, extent of surgery and reconstruction, radiation, chemotherapy, use of PEG and removal of PEG were evaluated.
The patients were 31 men and 12 women with a mean age of 57.4 years (range: 26 -74 years). All patients completed treatment with 60 Gy or more of radiotherapy and underwent chemotherapy with cisplatin, alone or with fluorouracil or with carboplatin alone. (Table 1 ) All patients underwent radiation therapy within 8 weeks after definitive surgery consisting of conventionally fractionated doses of 2 Gy in 5 weekly sessions. A large volume encompassing the primary site and all draining lymph nodes at risk received a dose of .40 -46 Gy. Regions that were adjacent to the high-risk area received a dose of .50 -60 Gy. Regions that were at high risk for malignant dissemination or that had inadequate resection margins received a total of 66 Gy in 33 fractions over a period of 6.5 weeks.
Two patients had difficulty with oral ingestion even before radiotherapy.
RESULTS
Prophylactic PEG tubes were used for enteral feeding in 34 (79.1%) of 43 patients and were not used in 9 patients. The PEG tubes that were used were later removed in 25 of the 34 patients (73.5%). The median period of use was 108 days. Among disease-free patients, the rate of feeding tube use was 34.1% (14 of 41 patients) at 6 months, 26.3% (10 of 38 patients) at 1 year, 21.6% at 18 months (8 of 37 patients) and 18.9% (7 of 37 patients) at 2 years. Because of cancer recurrence, eight patients used PEG tubes until their deaths. One patient, who could not ingest orally before radiotherapy because of dysphagia due to resection of the vagus and hypoglossal nerves, remains alive with a PEG tube. Only one disease-free patient was permanently dependent on PEG feeding. The rate and duration of PEG use by disease location are shown in Table 2 . The PEG was used for feeding in most patients with oral cancer (91.7%) or oropharyngeal cancer (100%) but was used at a much lower rate in patients with hypopharyngeal cancers (54.5%), particularly in those who had undergone pharyngolaryngoesophagectomy. Age .60 years was a factor predicting feeding tube dependence 1 year after (chemo-) radiotherapy (Table 3) .
DISCUSSION
Nutritional management is extremely important for the completion of treatment for head and neck cancer. Although the optimal method of nutritional management has been debated, the guidelines of the American Society for Parenteral and Enteral Nutrition state that enteral nutrition is more effective than parenteral nutrition and can be used to optimally maintain the patient's general condition.
In patients receiving chemoradiotherapy for head and neck cancer, hypoalimentation can be caused by numerous complications, including nausea due to chemotherapy, opportunistic infections due to myelotoxicity, mucositis due to radiotherapy or chemotherapy and pain from eczema. Hypoalimentation leads to weight loss and deterioration of the patient's general condition, which, in turn, can lead to a cessation or reduction of treatment, extended hospitalization and a reduced quality of life. For patients with head and neck cancer, PEG is a safe and well-established procedure for delivering nutrition and drugs. On the other hand, a patient's dependence upon PEG for nutrition can lead to a subsequent inability to ingest nutrition orally. Further retrospective studies have found significantly lower rates of persistent dysphagia 3 and 6 months after surgery in patients fed with nasogastric tubes than in patients fed with PEG tubes (23) .
Patients who undergo nasogastric feeding have their feeding tubes removed earlier than do patients who undergo PEG feeding (23, 25, 26) . This notion is supported by the work of Baredes et al. (24) , who have reported that PEG tube use leads to a longer period of non-oral feeding because of the deconditioning of the muscles of deglutition. A PEG may also produce feeding tube dependence in patients with dysphagia (27) . Kiyota et al. (28) have reported that among patients receiving adjuvant chemoradiotherapy, rates of feeding tube use at 3 months, 6 months and 1 year were 48, 40 and 20%, respectively.
In the present study, the median period of PEG use was 108 days, the rate of use at 2 years was 18.9% and only one patient was permanently dependent on PEG feeding; we consider these results to be satisfactory.
As a result of rehabilitation, there was no statistically significant difference in the rate of feeding tube use 1 year after (chemo-) radiation by primary site, reconstruction or concurrent chemotherapy. 
PEG dependence in post-operative therapy
The rate of PEG dependence after 1 year was higher in patients older than 60 years. Therefore, elderly patients have a greater need for rehabilitation than do younger patients.
PEG tubes were used by most patients with oral or oropharyngeal cancers (91.7 and 100%, respectively). On the other hand, the frequency of PEG use was much lower in patients with hypopharyngeal cancer (54.5%), particularly in patients who had undergone pharyngolaryngoesophagectomy. We speculate that a reason for this low rate of PEG use in patients with hypopharyngeal cancer is that areas of radiotherapyinduced mucositis are replaced with free jejunal grafts; because these grafts are poorly sensate, the patients feel little pain, and because the esophagus and respiratory tract are separated to prevent aspiration, oral feeding is relatively easy. Thus, we believe that PEG is unnecessary for patients who have undergone pharyngolaryngoesophagectomy.
Deglutition relies on sensory perception and the action of various organs in the head and neck region. Thus, the temporary absence of deglutition could result in functional decline. Patients being treated for head and neck cancer are likely to forgo deglutition due to either pain or lassitude, with patients using PEGs forgoing deglutition more readily and showing greater functional decline than do patients without PEGs. It is, therefore, necessary for patients with PEGs to continue ingestion and deglutition training.
At our institution, we provide the following support for patients and their families to allow early resumption of ingestion and independence from PEGs:
(1) Continuing guidance, in cooperation with a dentist, regarding oral hygiene and dryness, even after the completion of treatment. (2) Guidance on meals to enhance appetite in cases of dysgeusia and guidance to ensure adequate nutrition intake. (3) Guidance with regard to feelings of uneasiness after the removal of the PEG.
As a result of this support, nearly three-quarters of our patients could overcome their dependence on PEGs. In the future, we aim to study further adaptations to PEG feeding by improving the support system and accumulating a large number of cases for study.
CONCLUSION
Prolonged PEG use is not required in patients who undergo postoperative chemoradiotherapy and will not lead to dysphagia. Only one of our patients was permanently dependent on PEG feeding. We believe that our results are satisfactory. However, patients with oral or oropharyngeal cancer who are at a high risk for recurrence are more likely to require prophylactic PEG placement to maintain adequate nutritional status.
